98473700 - MULTIPLYING THE POSSIBILITIES

Information

• Trademark
• 98473700

• Source

• Serial Number

  98473700

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  March 28, 2024
  a year ago

• Transaction Date

  May 08, 2025
  9 months ago

• Status Date

  May 07, 2025
  9 months ago

• Location Date

  May 07, 2025
  9 months ago

• Status Code

  641

• Current Location

  TMO LAW OFFICE 111

  Employee Name

  SALTZMAN,DANIEL R

• Attorney Docket Number

  T-5009 US

  Attorney Name

  Joi A. White

  Law Office Assigned Location Code

  M20

• Owners

  • CAPSTAN THERAPEUTICS, INC.

Case File Statements

• GS0051: Pharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; pharmaceutical substances for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutics for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; therapeutic agents for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy systems used to express therapeutic proteins in vivo for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; biopharmaceuticals for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; medicines for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; drugs for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; vaccines; in vivo cell therapies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; cells for medical or clinical use; stem cells for medical purposes; cells for medical use; genetically engineered cells for medical purposes; gene therapy products, namely, lipid nanoparticle encapsulated nucleic acids; gene therapy preparations, in the nature of lipid nanoparticle encapsulated nucleic acids; gene therapy pharmaceutical preparations for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; gene therapy products, namely, genetically engineered cells for transplant purposes; targeted in vivo RNA technologies for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; targeted lipid nanoparticles for medicinal use; targeted lipid nanoparticles for durable cell reprogramming or cell engineering; targeted lipid nanoparticles for transient cell reprogramming or cell engineering; cell engineering platforms for treatment of human diseases, disorders and conditions; cell platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; in vivo cell engineering platforms for developing and engineering therapeutic cells, transient gene therapy, and durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders; transient in vivo cell engineering platforms for durable gene therapy for treatment of immunologic diseases, inflammatory diseases, autoimmune diseases, transplant rejection, graft versus host disease, cancers, fibrotic diseases, infectious diseases, aging-related pathologies, genetic diseases, and blood disorders

Case File Event Statements

• 3/28/2024 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 3/28/2024 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 10/9/2024 - a year ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 10/10/2024 - a year ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 10/10/2024 - a year ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 10/10/2024 - a year ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 4/2/2024 - a year ago

  3 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 1/8/2025 - a year ago

  9 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG

• 4/8/2025 - 10 months ago

  11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 4/8/2025 - 10 months ago

  10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 4/8/2025 - 10 months ago

  12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 5/7/2025 - 9 months ago

  15 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 5/7/2025 - 9 months ago

  13 - NON-FINAL ACTION WRITTEN Type: CNRT

• 5/7/2025 - 9 months ago

  14 - NON-FINAL ACTION E-MAILED Type: GNRT

• 1/8/2025 - a year ago

  8 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR